Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$209.39K$209.39Kderived— vs Q4 2018 Net Income-$4.56M-$4.56MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$1,623,304— Operating Incomederived-$4,035,564N/M Operating Cash Flowderived-$718,616N/M Free Cash Flowderived-$673,616N/M Margins · derivedGross margin-775.2%
Operating margin-1927.3%
Net margin-2176.5%
ended Dec 31, 2019 · filed May 22, 2020 · 143 d after period end